Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1061027/000156459021007784/snss-10k_20201231.htm
SEC Filings
SNSS Annual Reports
SNSS Quarterly Reports
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
10-Q Quarterly Report May 2018
10-Q Quarterly Report November 2017
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report November 2018
10-Q Quarterly Report August 2018
10-Q Quarterly Report May 2018
10-Q Quarterly Report November 2017
SNSS Corporate News
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Other Events
Security Holders Change February 2021
Event for Officers
Vote of Security Holders February 2021
Other Events February 2021
Event for Officers
Other Events December 2020
Bylaw Change
Event for Officers
Financial Exhibit
New Agreement
New Costs
Regulated Disclosure November 2020
Earnings Release
Financial Exhibit November 2020
Other Events September 2020
Bylaw Change
Financial Exhibit September 2020
Earnings Release
Financial Exhibit August 2020
Financial Exhibit
Other Events July 2020
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Other Events
Security Holders Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Other Events
Security Holders Change
February 2021
Event for Officers
Vote of Security Holders
Vote of Security Holders
February 2021
Other Events
February 2021
Event for Officers
Other Events
Other Events
December 2020
Bylaw Change
Event for Officers
Financial Exhibit
New Agreement
New Costs
Regulated Disclosure
Event for Officers
Financial Exhibit
New Agreement
New Costs
Regulated Disclosure
November 2020
Earnings Release
Financial Exhibit
Financial Exhibit
November 2020
Other Events
September 2020
Bylaw Change
Financial Exhibit
Financial Exhibit
September 2020
Earnings Release
Financial Exhibit
Financial Exhibit
August 2020
Financial Exhibit
Other Events
Other Events
July 2020
Last10K.com | 10-K Annual Report Wed Feb 24 2021
Document and Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2020 | Feb. 18, 2021 | Jun. 30, 2020 | |
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Amendment Flag | false | ||
| Document Period End Date | Dec. 31, 2020 | ||
| Document Fiscal Year Focus | 2020 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Registrant Name | SUNESIS PHARMACEUTICALS INC. | ||
| Entity Central Index Key | 0001061027 | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Interactive Data Current | Yes | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Public Float | $ 28,910,000 | ||
| Entity Common Stock, Shares Outstanding | 18,108,000 | ||
| Entity Shell Company | false | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity File Number | 000-51531 | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 94-3295878 | ||
| Entity Address, Address Line One | 395 Oyster Point Boulevard | ||
| Entity Address, Address Line Two | Suite 400 | ||
| Entity Address, City or Town | South San Francisco | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94080 | ||
| City Area Code | 650 | ||
| Local Phone Number | 266-3500 | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | ||
| Trading Symbol: | SNSS | ||
| Security Exchange Name | NASDAQ | ||
| Documents Incorporated by Reference | None. |
View differences made from one year to another to evaluate Sunesis Pharmaceuticals Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Sunesis Pharmaceuticals Inc.
Assess how Sunesis Pharmaceuticals Inc's management team is paid from their Annual Proxy
Sunesis Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Expense Highlight
Research and development expense consists primarily of clinical trial costs, which include: payments for work performed by our contract research organizations, clinical trial sites, labs and other clinical service providers and for drug packaging, storage and distribution; drug manufacturing costs, which include costs for producing drug substance and drug product, and for stability and other testing; personnel costs, including non-cash stock-based compensation; other outside services and consulting costs; and payments under license agreements.
-
Financial - Shares Highlight
Further decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.
-
Financial - Expense Highlight
As a result of the workforce reduction, Sunesis recognized one-time employee severance expenses of $1.3 million, which were included in accrued compensation on the consolidated balance sheet as of December 31, 2020, and noncash stock compensation expenses related to accelerated vesting of certain employee stock options of $0.1 million, both of which were recorded as operating expenses on the consolidated statement of operations and comprehensive loss for the year ended December 31, 2020.
-
Revenue - Product Highlight
In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under these agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.
-
Financial - Expense Highlight
The decrease of $3.1 million in 2020 was primarily due to a $1.8 million decrease in clinical expenses and a $0.2 million decrease in professional service expenses due to the decision not to advance our clinical trial for vecabrutinib into Phase 2, and a $1.6 million decrease in salary and personnel expenses due to lower headcount and less business-related travel, partially offset by $0.7 million increase in severance expense related to the workforce reductions in 2020.
-
Financial - Expense
General and administrative expense consists...Read more
-
Financial - Expense
Costs incurred for setting up...Read more
-
Financial - Shares
The Reverse Split affected the...Read more
-
Revenue - Product
We will pay Cantor a...Read more
-
Other - Other
When an implicit rate is...Read more
-
Revenue - Product
Gross proceeds from the sale...Read more
-
Revenue - Product
Gross proceeds from the sale...Read more
-
Other - Other
Net cash provided by investing...Read more
-
Other - Other
In some cases, forward-looking statements...Read more
-
M & A - Other
Our future funding requirements will...Read more
-
Financial - Expense
Costs related to patient enrollment...Read more
-
M & A - Other
Upon the terms and subject...Read more
-
Financial - Expense
The table below sets forth...Read more
-
Financial - Cash Flow
We have incurred significant operating...Read more
-
M & A - Other
To assist with this process,...Read more
-
M & A - Other
If we engage a development...Read more
-
Financial - Expense
Due to the above uncertainties...Read more
-
Financial - Expense
The increase of $0.3 million...Read more
-
Revenue - Product
Royalties: For arrangements that include...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parenthetical)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Company Overview
Company Overview - Additional Information (Detail)
Financial Instruments
Financial Instruments (Tables)
Financial Instruments - Additional Information (Detail)
Financial Instruments - Fair Value Of Company's Financial Assets Measured On Recurring Basis (Detail)
Guarantees And Indemnification
Guarantees And Indemnification - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Income Tax Provision Amount Computed By Applying Statutory Income Tax Rate (Detail)
Income Taxes - Loss Before Provision For Income Taxes (Detail)
Income Taxes - Reconciliation Of Unrecognized Tax Benefits (Detail)
Income Taxes - Significant Components Of Deferred Tax Assets (Detail)
Leases
Leases (Tables)
Leases - Additional Information (Details)
Leases - Schedule Of Maturity Of Lease Liability (Detail)
License Agreements
License Agreements - Additional Information (Detail)
Loss Per Common Share
Loss Per Common Share (Tables)
Loss Per Common Share - Computation Of Basic And Diluted Loss Per Common Share (Detail)
Loss Per Common Share - Schedule Of Potential Common Shares Issuable Pursuant To Outstanding Securities Excluded From Computation Of Diluted Loss Per Common Share (Detail)
Notes Payable
Notes Payable - Additional Information (Detail)
Other Accrued Liabilities
Other Accrued Liabilities (Tables)
Other Accrued Liabilities - Summary Of Other Accrued Liabilities (Detail)
Restructuring Costs
Restructuring Costs - Additional Information (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Summary Of Stock Option Activity For Company's Stock Option Plans (Detail)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense Related To Company's Stock-Based Awards (Detail)
Stock-Based Compensation - Summary Of Weighted-Average And Total Estimated Grant Date Fair Values Of Employee Stock Options Granted (Detail)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Additional Information (Detail)
Stockholders' Equity - Schedule Of Warrants To Purchase Shares Of Company's Common Stock (Detail)
Stockholders' Equity - Shares Of Common Stock Reserved For Future Issuance (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Material Contracts, Statements, Certifications & more
Sunesis Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits
Exhibit 4.1: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 21.1: Subsidaries Of The Registrant
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: SNSS
CIK: 1061027
Form Type: 10-K Annual Report
Accession Number: 0001564590-21-007784
Submitted to the SEC: Wed Feb 24 2021 6:06:16 AM EST
Accepted by the SEC: Wed Feb 24 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/snss/0001564590-21-007784.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...